HighTower Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

HighTower Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-200	Closed	-$350	–	3836
2024 Q3	$350	Buy	+200	New	+$16.7K	﹤0.01%	3697
2022 Q3	–	Sell	-400	Closed	-$4K	–	3174
2022 Q2	$4K	Buy	+400	New	+$31.8K	﹤0.01%	3132
2020 Q2	–	Sell	-500	Closed	-$2K	–	2437
2020 Q1	$2K	Hold	500	–	–	﹤0.01%	2167
2019 Q4	$3K	Buy	+500	New	+$37.8K	﹤0.01%	2237

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HighTower Advisors's BMRN Position: Q1 2026 in Review

HighTower Advisors reduced its BioMarin Pharmaceuticals (BMRN) stake by 1.6% in Q1 2026, selling an estimated $44.1K and leaving 47,276 shares worth $2.67M. The position accounts for ﹤0.01% of the portfolio, ranked #1548.

HighTower Advisors first reported a position in BMRN in Q4 2013 and has held it in 39 quarters since. The position peaked at $3.24M in Q1 2025. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

HighTower Advisors held 47,276 shares of BioMarin Pharmaceuticals worth $2.67M as of Q1 2026.
HighTower Advisors sold 756 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $44.1K.
BioMarin Pharmaceuticals made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #1548 holding.
HighTower Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2013 and has held it in 39 quarters since.
HighTower Advisors's BioMarin Pharmaceuticals position peaked at $3.24M in Q1 2025.
554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.